DENAS, GENTIAN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.163
EU - Europa 256
AS - Asia 252
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 1
Totale 3.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.160
CN - Cina 197
IT - Italia 63
SE - Svezia 63
FI - Finlandia 51
VN - Vietnam 27
GB - Regno Unito 23
DE - Germania 20
JP - Giappone 10
IN - India 8
NL - Olanda 8
SG - Singapore 7
UA - Ucraina 7
IE - Irlanda 6
BE - Belgio 5
EU - Europa 5
FR - Francia 4
CA - Canada 3
RU - Federazione Russa 2
BR - Brasile 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
KW - Kuwait 1
KZ - Kazakistan 1
MY - Malesia 1
PT - Portogallo 1
RO - Romania 1
Totale 3.677
Salva come PNG Salva come JPEG
Città #
Fairfield 613
Woodbridge 319
Chandler 318
Ashburn 298
Ann Arbor 243
Houston 235
Cambridge 233
Seattle 195
Wilmington 183
Beijing 70
San Diego 50
Princeton 48
Medford 45
Des Moines 40
Nanjing 29
Dong Ket 27
Helsinki 24
Boardman 23
Padova 20
Roxbury 17
Nanchang 12
New York 12
Shenyang 12
Guangzhou 9
Falls Church 7
Hefei 7
Dearborn 6
Dublin 6
Hebei 6
Jinan 6
London 6
Redwood City 6
Singapore 5
Zhengzhou 5
Changsha 4
Jiaxing 4
Brussels 3
Genoa 3
Kharkiv 3
Kunming 3
Mestre 3
Milan 3
Ningbo 3
Norwalk 3
Pune 3
Tappahannock 3
Tokyo 3
Bertinoro 2
Borås 2
Groningen 2
Jacksonville 2
Las Vegas 2
Ogden 2
Shanghai 2
Taiyuan 2
Tianjin 2
Almaty 1
Amsterdam 1
Arzignano 1
Castello di Godego 1
Chongqing 1
Columbus 1
Edinburgh 1
Falkenstein 1
Fragneto Monforte 1
Geislingen an der Steige 1
Hendon 1
Kilburn 1
Kuala Lumpur 1
Kuwait City 1
Lanzhou 1
Leuven 1
Lisbon 1
Los Angeles 1
Orange 1
Pearland 1
Phoenix 1
Quzhou 1
Redmond 1
Saint Louis 1
Stockholm 1
São Paulo 1
Taizhou 1
Vigonza 1
Walnut 1
Xian 1
Yuncheng 1
Zurich 1
Totale 3.226
Salva come PNG Salva come JPEG
Nome #
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 154
Diagnosis and therapy of antiphospholipid syndrome 121
Laboratory testing for antiphospholipid syndrome 117
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 112
An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation 110
Interpretation of laboratory data and need for reference laboratories. 106
The Paradox of the Lupus Anticoagulant: History and Perspectives 106
APS - Diagnostics and challenges for the future 105
Antiphospholipid syndrome and the heart: A case series and literature review 101
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 100
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 97
A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures 95
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 95
An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions 94
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 94
Correct laboratory approach to APS diagnosis and monitoring 92
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 91
Dyspnoea in a young woman: the opposite of every truth is just as true 89
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 89
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study 86
To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort 83
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 83
Optimizing quality care for the oral vitamin K antagonists (VKAs) 83
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 82
The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients 81
Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation 80
One-Year Outcomes After Transapical Echocardiography-Guided Mitral Valve Repair 80
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study 79
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective 79
Secondary prevention in thrombotic antiphospholipid syndrome. 76
Normal left ventricular mechanics by two-dimensional speckle-tracking echocardiography. Reference values in healthy adults 76
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 75
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation 73
Laboratory Diagnostics of Antiphospholipid Syndrome 72
Reference values of right ventricular longitudinal strain by speckle tracking echocardiography in 219 healthy volunteers 70
Investigational anticoagulants for hematological conditions: a new generation of therapies 70
Relationship of 3D left ventricular mass with systolic and diastolic function indices in hypertrophic cardiomyopathy 69
Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis 64
Reference values for 3D echo parameters describing left ventricular mechanics obtained by vendor-independent software 63
Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study 62
The role of platelets in antiphospholipid syndrome 57
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma 55
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. 35
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey 22
Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study 14
Totale 3.737
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.454
article - articoli 12.454
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019336 0 0 0 0 0 0 0 0 0 0 181 155
2019/2020964 114 51 12 59 120 67 116 121 121 98 62 23
2020/2021446 36 31 24 30 13 36 23 40 73 24 47 69
2021/2022713 40 70 89 52 17 48 41 80 29 16 59 172
2022/2023557 116 67 15 74 84 63 2 40 53 4 33 6
2023/2024189 7 34 25 22 7 34 14 27 5 5 9 0
Totale 3.737